No person-to-person spread has been detected, but that doesn’t mean an H5N1 avian influenza pandemic isn’t possible or even ...

MRNA’s first problem is the lack of near-term catalysts beyond infectious disease vaccines. The stock often swings on disease outbreaks, such as H5N1 avian flu last year, but this is unlikely to ...

Moderna has been testing an mRNA candidate for influenza viruses like the H5 and H7 strains that are seen as pandemic threats ...

We recently compiled a list of the These 10 Companies Led Gains on Wednesday. In this article, we are going to take a look at ...

Before beginning the discussion of where this company is going, let's set expectations appropriately. Moderna won't be ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

The misery of the common stomach flu may be coming to an end. Pharmaceutical company Moderna has launched a large-scale Phase ...

Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The current public-health risk is low, but the CDC is working with states to monitor people with animal exposure.

Cases of norovirus infections are surging, but coming up with a way to prevent them has proven to be a challenge.

Merck shares trade at a significant discount to peers. The company faces challenges, but there are reasons to be bullish.